Asimov introduces its AI-driven fourth generation CHO Edge System with increased titer guarantee

Published: 31-Jul-2024

Enabling superior cell line development with AI and advanced genetic optimisation

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of its fourth generation CHO Edge System. With an increased typical titer range of 5-11 g/L across modalities before any upstream process optimisation, the new system has been developed to optimise expression across a breadth of biologic architectures and increase the likelihood of high titer cell lines.

The system’s improved robustness has allowed Asimov to increase its minimum CLD titer guarantee for IgG monoclonal antibodies to 5 g/L. If the lead clone does not hit this benchmark, it is still transferred to the partner, but the service fee and all commercial use licence fees are waived.

The fourth generation CHO Edge System updates expression vector architectures, genetic parts selection, and process methodologies. In addition, the new system incorporates a suite of AI models to predict signal peptide cleavage, RNA splicing, and upstream process optimisation. Customers can access these advanced capabilities by licensing the CHO Edge System or as part of Asimov’s Cell Line Development Service.

Alec Nielsen, co-founder and CEO of Asimov said: “Our fourth generation CHO Edge System incorporates learnings from a wide range of molecules, and an array of proprietary data-driven AI models. We have upgraded the vector architectures, genetic parts selection, and predictive modelling across multiple biological processes. While we always target titers in excess of 10 g/L in our CLD process, we can now guarantee a minimum of 5 g/L for IgG molecules. By offering a titer guarantee, we aim to set a new standard for cell line development in the industry and redefine the expectations of therapeutic developers.”

The CHO Edge System incorporates a GMP-banked CHO-K1 GS knock-out host (or a GS-Fut8 double knockout), a hyperactive transposase, a library of over 1000 characterised genetic parts and advanced computational models. Asimov reliably generates stable cell lines with high titer and product quality by using the CHO Edge System to optimise the expression vector across modalities.

For more information about Asimov and the CHO Edge System, please visit https://www.asimov.com/cho

 

 

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
  2. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like